Department of OUTCOMES RESEARCH

Slides:



Advertisements
Similar presentations
Ryan Hampton January  Risks and benefits of surgery  Timing of surgery  Type of Surgery  Goal is to uncover undiagnosed problems or treat prior.
Advertisements

Presenter Disclosure Information Paul M Ridker, MD, FACC Dr Ridker is listed as a co-inventor on patents held by the Brigham and Women’s Hospital that.
Management of Acute Myocardial Infarction Minimal Acceptable vs Optimal Care Hussien H. Rizk, MD Cairo University.
Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.
VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.
Beta Blockade and the Heart John Hakim, M.D Cardiology Fellow West Virginia University Division of Cardiology.
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
Department of OUTCOMES RESEARCH
Department of O UTCOMES R ESEARCH. Causes of Death Bartels, et al., 2013, Anesthesiology.
Cardioprotective Agents in the Total Joint Arthroplasty Patient: Are We Doing Enough? Eric Schwenk MD*, Kishor Gandhi MD MPH*, Javad Parvizi MD^, Eugene.
Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.
PEACE BNP: Omland, T. et al. J Am Coll Cardiol 2007; 50:205–14 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. Prognostic.
Morbidity and Mortality in Contemporary CAD Patients With Hypertension Treated With Either a Verapamil/Trandolapril or Beta-Blocker/Diuretic Strategy (INVEST):
Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)
Translating evidence into practice: cardiac patients for non-cardiac surgery H Yang Professor & Chair Department of Anesthesia.
AA-2-1 Jerome D. Cohen, MD, FACC, FACP Professor of Internal Medicine / Cardiology Director, Preventive Cardiology Programs St. Louis University Health.
Journal Club : Relationship between Intraoperative Mean Arterial Pressure and Clinical Outcomes after Noncardiac Surgery Toward an Empirical Definition.
PJ Devereaux, Population Health Research Institute, Hamilton, Canada on behalf of POISE-2 Investigators PeriOperative ISchemic Evaluation-2 Trial POISE-2POISE-2.
Daniel I. Sessler Department of O UTCOMES R ESEARCH Cleveland Clinic on behalf of POISE-2 Investigators PeriOperative ISchemic Evaluation-2 Trial POISE-2POISE-2.
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
Prognostic Value of B-Type Natriuretic Peptides in Patients with Stable Coronary Artery Disease The PEACE trial Omland T, et al. JACC 2007;50:
PJ Devereaux, MD, PhD McMaster University
Clinical Outcomes with Newer Antihyperglycemic Agents
FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
  Aldosterone Targeted NeuroHormonal CombinEd with Natriuresis TherApy – Heart Failure Trial ATHENA-HF Trial Javed Butler, M.D., M.P.H, M.B.A. On behalf.
Antonio Coca, MD, PhD, FRCP, FESC
Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD,
Prognostic Value of B-Type Natriuretic Peptides in Patients With Stable Coronary Artery Disease: The PEACE Trial Torbjørn Omland, MD, PHD, MPH, Marc S.
What should the Systolic BP treatment goal be in patients with CKD?
Clinical Outcomes with Newer Antihyperglycemic Agents
Nephrology Journal Club The SPRINT Trial Parker Gregg
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
Myocardial Injury after Noncardiac Surgery and Association with Short Term Mortality Wilton A van Klei Anesthesiologist and acting chair Department Anesthesiology,
Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals
Hypertension JNC VIII Guidelines.
Blood Pressure and Age in Controlling Hypertension
Department of OUTCOMES RESEARCH
The European Society of Cardiology Presented by Dr. Bo Lagerqvist
HOPE: Heart Outcomes Prevention Evaluation study
The SELECT-ACS Trial Montreal Heart Institute
Is There a Role for Aspiration in STEMI?
POISE-2 PeriOperative ISchemic Evaluation-2 Trial
Heart Rate, Life Expectancy and the Cardiovascular System: Therapeutic Considerations Cardiology 2015;132: DOI: / Fig. 1. Semilogarithmic.
AIM HIGH Niacin plus Statin to prevent vascular events
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
Discussion / Conclusions
ASCEND Randomized placebo-controlled trial of aspirin 100 mg daily in 15,480 patients with diabetes and no baseline cardiovascular disease Jane Armitage.
Advances in Management of Perioperative Hypotension: It Takes a Team
ACTIVE A Effects of Addition of Clopidogrel to Aspirin in Patients with Atrial Fibrillation who are Unsuitable for Vitamin K Antagonists.
Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD,
Systolic Blood Pressure Intervention Trial (SPRINT)
The following slides highlight a presentation at the Late-Breaking Clinical Trials session of the American Heart Association Scientific Sessions, November.
CRASH 2 Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2):
Dabigatran in myocardial injury after noncardiac surgery
The Hypertension in the Very Elderly Trial (HYVET)
These slides highlight an educational report from a late-breaking clinical trials presentation at the 58th Annual Scientific Session of the American College.
Dr. PJ Devereaux on behalf of POISE Investigators
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.
Dr. PJ Devereaux on behalf of POISE Investigators
Dabigatran in myocardial injury after noncardiac surgery
Clonidine in Patients Having Noncardiac Surgery
What oral antiplatelet therapy would you choose?
ARISE Trial Aggressive Reduction of Inflammation Stops Events
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effect of ivabradine on recurrent hospitalization for worsening heart failure:
Dabigatran in myocardial injury after noncardiac surgery
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
EMPA-REG OUTCOME: Cumulative incidence of the primary outcome
Presentation transcript:

Department of OUTCOMES RESEARCH

Perioperative Myocardial Injury Daniel I. Sessler, M.D. Michael Cudahy Professor and Chair Department of OUTCOMES RESEARCH Cleveland Clinic www.or.org

Perioperative Mortality Intraoperative mortality rare Thirty-day mortality 1% in the United States 2% worldwide for inpatients ≥45 years old 1000 times more common than intraop mortality “Myocardial Injury after Non-cardiac Surgery” = MINS

Surgery is a Major Cause of Death Bartels, Anesthesiology 2013

Causes of Postoperative Death (%) Adjusted HR (95% CI) Attributable Fraction Myocardial injury 18 4 (3-5) 24 Major bleeding 14 3 (2-4) Sepsis 4 5 (4-7) 9 New AF 1 2 (1-3) 2 Stroke 0.3 5 (3-10) VISION: Devereaux, JAMA 2017

Common, Silent, and Deadly MI incidence 4% among inpatients >45 years Mortality is 4% at 30 days Myocardial Injury after Non-cardiac Surgery “MINS” 18% of inpatients >45 yrs have troponin increase 93% without symptoms It’s not just “troponitis” 8.5% have MI, cardiac arrest, or death

High-sensitivity Troponin T Only 22% met Universal Definition of MI — but they still died Population attributable risks: Age – 40%, MINS – 34%, and sepsis – 30%. Mortality increase by squares: 2, 3, 5, 8, 15.

MINS (Troponin T Increase) Outcome No MINS (n = 13,822), % MINS (n = 1,194), % OR (95% CI) Nonfatal arrest 0.1 0.8 15 (6-37) CHF 1.0 9.4 10 (8-13) Stroke 0.4 1.9 5 (3-8) Death 1.1 9.8 Composite 2.4 18.8 10 (8-12) VISION: Devereaux JAMA 2012; Botto, Anesthesiology 2014

Post-Op Troponin & Long-term Death Beattie, JACC 2017

Professional Society Guidance Universal Definition of MI “Routine monitoring of cardiac biomarkers in high-risk patients … after major surgery is therefore recommended.” Canadian Cardiovascular Society “Daily troponin measurements for 2-3 days in patients with moderate cardiovascular risk

Troponin Monitoring Who: inpatient surgery and: When Age >45 years and ≥1 risk cardiovascular risk factor Age >65 years When Preoperatively 25% elevated preoperatively, mostly chronically First two days while hospitalized 94% of elevations detected within 2 days Response thresholds Preoperative-to-postoperative increase >5 ng/L and postoperative >20 ng/L Postoperative >65 ng/L

Elevated Troponin? Cardiology consult Occasional patients need catheterization ± angioplasty Discussion of risk Aspirin (22% secondary reduction) ± statins or ACEIs Only one-third of MINS patients current treated Heart rate and hypertension control Lifestyle Smoking cessation Reasonable diet Exercise

Risk Prediction Revised Cardiac Risk Index Exercise tolerance Well validated But assigns >50% patients to “intermediate risk” Exercise tolerance Neither patients nor physicians estimate well Unclear if exercise tolerance is predictive Stress echo Expensive and virtually useless CT angiography Worsens clinical risk assessment

Brain Natiuretic Protein Rodseth, J Am Coll Card, 2014 Enhances Revised Cardiac Risk Index Correctly identifies 16% more high-risk patients Correctly identifies 15% more low-risk patients BNP MI or Death Risk <100 ng/mL 5% >250 27% NT pro-BNP Risk of MI or Death <300 ng/mL 5% 901-3000 26% >3000 40% Optimal ng/mL threshold is BNP <92 or NT pro-BNP <300

Preoperative Troponin Nagele, Am Heart J, 2013

Prevention: POISE-1 8,350 at-risk inpatients >45 years randomized Metoprolol 100 mg extended-release for 30 days Placebo Primary outcome: death, MI, cardiac arrest Fewer composite outcomes: 5.8% vs. 6.9% More strokes: 4.1% vs. 2.2% More death: 3.1% vs. 2.3% Beta blockers prevent MI, but increase death Devereaux, Lancet, 2008

Prevention: ENIGMA-2 Background Hypothesis N2O increases plasma homocysteine N2O impairs endothelial function Hypothesis N2O increases 30-day death or major CV events MI required troponin elevation & clinical event Randomized trial in 7,000 high-risk patients 70% nitrous oxide 70% nitrogen Myles, Lancet, 2014

Prevention: POISE-2 Surgery Aspirin Clonidine Inflammatory response activates platelets Promotes tachycardia Aspirin Impairs platelet aggregation Prevents non-operative primary & secondary MI Clonidine Moderates central sympathetic activation Heart rate control Less hypotension than beta blockers Devereaux, NEJM (2 papers) 2014

POISE-2 Design Inpatients >45 years at cardiovascular risk Blinded 2 X 2 factorial trial Aspirin 100 mg/day vs. placebo for 7 or 30 days Clonidine 75 µg/day vs. placebo for 72 hours Primary outcome Death or MI within 30 days MI required troponin elevation and clinical events Safety outcomes Life-threatening bleeding (i.e., required reoperation) Clinically important hypotension (syst < 90 mmHg & Rx) Clinically important bradycardia (HR <55/min & Rx)

Aspirin, Death & MI 20% increase in major bleeding

POISE-2 Results, Clonidine 30-50% increase in hypotension & bradycardia %

No Safe Prophylaxis for MI POISE-1: Beta blockers Decrease myocardial infarctions by 30% Cause devastating strokes and death ENIGMA-2 Nitrous oxide has no effect on MI POISE-2 Aspirin does not reduce MI; life-threatening bleeding Clonidine doesn’t reduce MI; bradycardia & hypotension

Association Between MAP & Death Mascha, Anesth 2015

Hypotension & Myocardial Injury

Hypotension and AKI Salmasi, Anesthesiology 2017

Vasopressors do not Worsen AKI 1,080 Matched patients Major spine surgery With and without phenylephrine infusion Farag, unpublished

Timing of Hypotension Maheshwari, unpublished

Futier, et al. JAMA 2017 Randomized trial, n=292 high-risk patients Norepinephrine to keep systolic pressure ±10% Ephedrine for systolic pressure <80 mmHg Primary outcome Systemic inflammation and organ failure 56/147 versus 75/145 patients Relative risk 0.73 [95% CI: 0.56, 0.94], P=0.02 Considerations Actual difference in systolic pressure only 6 mmHg Most difference in kidney injury & mental status Only 1 myocardial infarction

Hold ACEIs and ARBs Roshanov, Anesthesiology 2017. Holding ACEIs and ARBs on the day of surgery reduced hypotension and the risk of a composite of death, MINS, or stroke by about 20%.

Tachycardia Hardly Matters Ruetzler, unpublished Abbott reports increased MINS & MI with heart rate >100 b/min; A&A 2017

High Risk on Surgical Wards Heart attacks occur postoperatively 94% within two days 50% of deaths during initial hospitalization Ward hypoxemia and hypotension Common, profound, and prolonged Cannot be reliably predicted

Blinded Saturation Over Time Sun, A&A 2015

Hypoxemic Episode Duration Nurses missed 90% of patients who had 1 continuous hour of saturation <90% 34

Continuous Ward Hypotension (n=265) Nurses missed 70% of patients with MAP <65 mmHg for 15 minutes Chang, unpublished

Postop Hypotension Matters Too Sessler Anesthesiology, in press Adjusted for baseline risk and hypotension in previous periods

Pain and MINS Adjusted for baseline risk, type and duration of surgery, etc. Turan, unpublished

ICU Hypotension & MINS Khanna, unpublished MINS/Mortality <90 mmHg ≥90 mmHg Hazard ratio (95% CI) (Per 10 mmHg difference) (versus 90 mmHg) Khanna, unpublished

ICU Hypotension & AKI

Summary Myocardial injury after non-cardiac surgery Monitor troponin Common, deadly, and mostly silent Monitor troponin Inpatients >45 years at risk, & all inpatients >65 years Preoperatively and first two postoperative days while hospitalized Risk stratification RCRI, NT-Pro-BNP, and preoperative troponin all help No known safe prophylaxis Keep intraoperative MAP >65mmHg; prevent postoperative hypotension Hold ACEIs and ARBs on the day of surgery

Department of OUTCOMES RESEARCH